27 March 2008: Today, the Board of Directors of NorDiag approved the financial statements for 2007. Compared to the preliminary results for 2007, net profit after taxes and minority interests for the group is improved by NOK 1.9 million. This is due to a reversal of deferred tax cost. The balance sheet is also increased with NOK 9 million due to increased goodwill and deferred tax in connection with the acquisition of the Genpoint Group.

Contact: CFO Tone Kvåle, phone 915 19576.

NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag is listed on Oslo Stock
Exchange with the ticker NORD. For further information - www.nordiag.com